BARINTHUS BIOTHERAPEUTICS SRL

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: -

Employees: -

Market Cap: $49.2M

Website

Clinical Trials

VTP-1000 in Adults With Celiac Disease

Early Phase 1

Recruiting

Conditions: Celiac Disease

Interventions: Other: Matched Placebo
Biological: VTP-1000

First Posted Date: 2024-03-15

Last Posted Date: 2024-12-12

Lead Sponsor: Barinthus Biotherapeutics

Target Recruit Count: 45

Registration Number: NCT06310291

Locations: 🇺🇸
GCP Research, Saint Petersburg, Florida, United States
🇺🇸
North Carolina Clinical Research, Raleigh, North Carolina, United States
🇺🇸
Parexel EPCU Baltimore, Baltimore, Maryland, United States

and more 1 locations

Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Prostate Cancer

First Posted Date: 2022-11-15

Last Posted Date: 2024-10-01

Lead Sponsor: Barinthus Biotherapeutics

Target Recruit Count: 144

Registration Number: NCT05617040

Locations: 🇺🇸
Cornell University, New York, New York, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

and more 4 locations

Efficacy of VTP-300 in Chronic Hepatitis B Infection

Phase 2

Active, not recruiting

Conditions: Chronic Hepatitis B

Interventions: Biological: ChAdOx1-HBV
Biological: MVA-HBV
Biological: Nivolumab

First Posted Date: 2022-04-25

Last Posted Date: 2024-11-20

Lead Sponsor: Barinthus Biotherapeutics

Target Recruit Count: 120

Registration Number: NCT05343481

Locations: 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇭🇰
Prince Of Wales Hospital, Hong Kong, Hong Kong
🇨🇳
Dalin Tzu Chi Hospital, Chiayi City, Taiwan

and more 15 locations

First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV

Phase 1

Completed

Conditions: Hepatitis B

Interventions: Biological: ChAdOx1-HBV
Biological: MVA-HBV
Biological: Nivolumab

First Posted Date: 2021-03-03

Last Posted Date: 2024-08-13

Lead Sponsor: Barinthus Biotherapeutics

Target Recruit Count: 55

Registration Number: NCT04778904

Locations: 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷
Keimyung University Dongsan Hospital, Daegu, Korea, Republic of

and more 9 locations

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

Phase 1

Completed

Conditions: HPV Infection
CIN1

Interventions: Biological: ChAdOx1-HPV
Biological: Placebo
Biological: MVA-HPV

First Posted Date: 2020-10-29

Last Posted Date: 2024-07-31

Lead Sponsor: Barinthus Biotherapeutics

Target Recruit Count: 108

Registration Number: NCT04607850

Locations: 🇧🇪
UZA, Antwerp, Belgium
🇧🇪
UZ Gent, Gent, Belgium
🇧🇪
UZ Brussel, Brussels, Belgium

and more 13 locations

First in Human Study of ChAdOx1-HBV

Phase 1

Completed

Conditions: Hepatitis B
Healthy

Interventions: Biological: ChAdOx1-HBV

First Posted Date: 2020-03-06

Last Posted Date: 2022-07-25

Lead Sponsor: Barinthus Biotherapeutics

Target Recruit Count: 47

Registration Number: NCT04297917

Locations: 🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Headington, Oxford, United Kingdom
🇬🇧
Medicines Evaluations Unit, Manchester, United Kingdom
🇬🇧
University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom

and more 1 locations

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Saline
Biological: MVA-NP+M1
Biological: H3N2 (A/Belgium/2417/2015)

First Posted Date: 2019-03-20

Last Posted Date: 2021-03-18

Lead Sponsor: Barinthus Biotherapeutics

Target Recruit Count: 145

Registration Number: NCT03883113

Locations: 🇧🇪
SGS Life Sciences, Clinical Pharmacology Unit (CPU), Antwerp, Belgium

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

Phase 2

Terminated

Conditions: Influenza

Interventions: Biological: MVA-NP+M1
Drug: Saline

First Posted Date: 2019-03-19

Last Posted Date: 2021-04-26

Lead Sponsor: Barinthus Biotherapeutics

Target Recruit Count: 2364

Registration Number: NCT03880474

Locations: 🇦🇺
Scientia Clinical Research, Sydney, New South Wales, Australia
🇦🇺
University of Sunshine Coast (USC), Sippy Downs, Queensland, Australia
🇦🇺
Mater Research, South Brisbane, Queensland, Australia

and more 4 locations

Improved Novel VaccIne CombinaTion InflUenza Study

Phase 2

Terminated

Conditions: Influenza

Interventions: Drug: Seasonal influenza vaccine
Drug: MVA-NP+M1
Drug: Sodium chloride

First Posted Date: 2017-10-03

Last Posted Date: 2018-11-23

Lead Sponsor: Barinthus Biotherapeutics

Target Recruit Count: 862

Registration Number: NCT03300362

Locations: 🇬🇧
The Boathouse Surgery, Pangbourne, Berkshire, United Kingdom
🇬🇧
Wokingham Medical Centre, Wokingham, Berkshire, United Kingdom
🇬🇧
Windrush Health Centre, Witney, Oxfordshire, United Kingdom

and more 2 locations

A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1

Early Phase 1

Completed

Conditions: Human Volunteers

Interventions: Biological: MVA-NP+M1

First Posted Date: 2017-09-11

Last Posted Date: 2017-11-14

Lead Sponsor: Barinthus Biotherapeutics

Target Recruit Count: 6

Registration Number: NCT03277456

Locations: 🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy